Interchangeability Won’t Solve US Biosimilar Market’s Woes, FDA’s Gottlieb Says

FDA's Biosimilar Action Plan aims to boost approvals, but Commissioner Gottlieb says he's had a change of heart about how much impact an interchangeability designation can have on market uptake.